Senolytics and/or aerobic exercise in aging mice: less cardiac cell senescence, better heart function
In 12-month-old mice treated for 9 months, senolytics (Dasatinib + Quercetin), aerobic exercise, or both lowered senescent heart cells and improved heart function versus naturally aged mice; the abstract does not report a synergistic advantage of combining them. [1]
Automatic summary · not editorially reviewed
The key findings
The authors state that neither senolytics nor aerobic exercise had been evaluated as long-term prevention, nor whether combining them adds benefit. [1]
Twelve-month-old male and female mice were treated for 9 months with vehicle, exercise, Dasatinib + Quercetin, or both combined. [1]
Senolytics, exercise, or both lowered senescent heart cell markers and improved myocardial and diastolic function versus naturally aged mice. [1]
The source at a glance
- Study type / format
- Animal intervention study (abstract)
- Population / context
- Male and female C57BL/6N mice, 12 months old at the start of a 9-month intervention.
- Summary based on
- Study abstract
- Original publication
- October 1, 2026
Aging mouse hearts and the senescence question
The abstract frames aging as the main risk factor for cardiac dysfunction, with senescent heart muscle cells and interstitial cells accumulating with age. These cells show persistent DNA damage, mitochondrial dysfunction and inflammation, which the authors link to impaired ventricular relaxation and contraction. Senolytics selectively remove senescent cells; aerobic exercise is described as a non-drug approach that may influence senescence. The authors note neither had been tested as long-term prevention, nor whether combining them adds benefit.
Supporting source [1]
Nine-month treatment in 12-month-old mice
Male and female C57BL/6N mice, 12 months old at the start, were randomly assigned and treated for 9 months: naturally aged vehicle (n = 12), aerobic exercise (n = 11), senolytics Dasatinib + Quercetin (n = 15), or both combined (n = 16). Compared with naturally aged mice, senolytics, exercise, or both significantly lowered the proportion of p16+, p21+ and γ-H2AX+ heart muscle and interstitial cells and improved myocardial performance and diastolic function. At the whole-heart level, p16 and p21 protein rose with age but was not changed by any intervention, nor was the senescence-associated secretory phenotype.
Supporting source [1]
What the abstract does and does not show
The authors conclude that long-term exercise or senolytics limit senescence at the cellular level in the heart muscle and improve ventricular function, calling both promising strategies against age-related cardiac dysfunction. This is an abstract only; the full text was not reviewed. The abstract reports no direct statistical comparison showing that combining the two is better than either alone, so the hypothesised synergy is not confirmed here. These are mouse findings and do not establish human heart or lifespan benefits.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. The abstract reports no direct statistical test of whether the combination outperforms either approach alone, so the hypothesised synergy is unconfirmed. Findings are in mice and do not establish human heart or lifespan benefits.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Bevington RT, Johnson AL, Hockey BL, Fajardo VA, Parise G. · europepmc.org · October 1, 2026